StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > For Dummies

<< Previous

Bullboard Posts

Next >>

Comment by davewhoon Apr 01, 2021 10:25am

174 Views

Post# 32922317

RE:RE:For Dummies

could very well be that was the road Szls wanted to go with Aristotle. But is it possible the authorities said no. A new first to market novel pan cancer test should require Oncology oversight would seem logical? Some things only James knows. They certainly seemed to be waiting for something in Q1. On going talks? Who knows.
FWIW OTC shows no follow through with little volume so far. IMO

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities